f Post-Approval Studies (PAS) Database
Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

ConservePlus Longer-Term PAS


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Terminated
Application Number /
Requirement Number		 P030042 / PAS001
Date Original Protocol Accepted 11/03/2009
Date Current Protocol Accepted 07/16/2010
Study Name ConservePlus Longer-Term PAS
Device Name CONSERVE PLUS TOTAL RESURFACING HIP SYSTEM
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Historical Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives Multi-center, prospective, historically controlled
Study Population Patients who were previously enrolled in the CONSERVE Plus Total Resurfacing Hip System IDE
Sample Size 353 patients
Key Study Endpoints The primary endpoint is clinical success at 120 months post-operative for each patient.
Follow-up Visits and Length of Follow-up Patients will undergo clinical and radiographic evaluation post-operatively at years 5,8, & 10. Patients will also have serum levels of cobalt and chromium ions and renal function data collected postoperatively at years 5, 8, & 10.

Length of follow-up : Until each patient has reached 10 years, which will be in 2016.


ConservePlus Longer-Term PAS Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 01/16/2011 01/12/2011 On Time
1 year report 05/04/2011 05/06/2011 Overdue/Received
18 month report 01/13/2012 01/13/2012 On Time
2 year report 05/16/2012 12/19/2012 Overdue/Received


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-